Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 30 results for ranibizumab

  1. Stopping rules for antiangiogenic treatment for late AMD (wet):- When should anti-vascular endothelial growth factor (VEGF) treatment be suspended or stoppedin people with late AMD (wet)?

    inconvenience, risk of adverse events and – especially when aflibercept or ranibizumab is used – substantial costs. People typically...

    Research recommendation
    Published
    13 November 2018

  2. Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)

    NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .

    Medtech innovation briefing
    Published
    24 April 2018

  3. Age-related macular degeneration (NG82)

    This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.

    NICE guideline
    Published
    23 January 2018
    View recommendations

    Sections for NG82

  4. Aflibercept for treating choroidal neovascularisation (TA486)

    Evidence-based recommendations on aflibercept (Eylea) for treating choroidal neovascularisation in adults.

    Technology appraisal guidance
    Published
    1 November 2017
    View recommendations

    Sections for TA486

  5. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

    Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA409

  6. Aflibercept for treating diabetic macular oedema (TA346)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA346

  7. NICE concluded that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema secondary to retinal vein occlusion should be conducted.

    further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema...

    Research recommendation
    Published
    9 June 2015

  8. NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be conducted.

    further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular...

    Research recommendation
    Published
    9 June 2015

  9. Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by macular oedema from central retinal vein occlusion in adults.

    Technology appraisal guidance
    Published
    26 February 2014
    View recommendations

    Sections for TA305

  10. Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

    Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Published
    24 July 2013
    View recommendations

    Sections for TA294

  11. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.

    Technology appraisal guidance
    Published
    27 July 2011
    View recommendations

    Sections for TA229

  12. Limited macular translocation for wet age-related macular degeneration (HTG215)

    Evidence-based recommendations on limited macular translocation for wet age related macular degeneration. This involves cutting and moving the macula on an a nearby healthier area of the retina.

    HealthTech guidance
    Published
    19 May 2010
    View recommendations

    Sections for HTG215

  13. Ranibizumab for the treatment of diabetic macular oedema (TA237)

    This guidance has been updated and replaced by NICE technology appraisal guidance 274.

    Withdrawn guidance

  14. Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]

    Awaiting development Reference number: GID-TA10879 Expected publication date:  11 November 2026

    Technology appraisal guidance
    Awaiting development

  15. Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]

    Awaiting development Reference number: GID-TA11065 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development